Background: Completion of the recommended 9-month course of isoniazid to treat latent tuberculosis infection in children remains poor and is often affected by adverse effects, including hepatitis, to medication. We evaluated the frequency of isoniazid therapy completion and factors associated with failure to complete therapy in patients aged 0-18 years. Methods: We performed a retrospective review of medical records for patients aged 0-18 years who were referred for isoniazid therapy between January 2005 and August 2011 at 2 California county sites: a public health department and a pediatric latent tuberculosis infection clinic. Medication adherence to isoniazid therapy was measured by monthly pill count. Results: There were 1872 eligible patients who were referred for isoniazid therapy. Of the 1587 patients who met inclusion criteria and initiated treatment, 1235 patients (78%) completed the 9-month therapy, including 1046 of 1308 patients aged <15 years (80%) and 189 of 268 patients aged 15-18 years (71%). Factors that were significantly associated with failure to complete therapy included age 15-18 years, non-Hispanic race, development of hepatitis, and symptoms of adverse effects. The association between age and the development of hepatitis was similar for male and female patients.
Introduction
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America guidelines, endorsed by the American Academy of Pediatrics, recommend a 9-month course of isoniazid to treat latent tuberculosis infection (LTBI) in children and adolescents [1] . Young children have a greater risk of progressing to active tuberculosis (TB), and children have more years to develop TB [2] . The frequency of completion of a 9-month isoniazid course, defined as 270 doses taken within 12 months, is low in children and adolescents (40.3-75%) [3] [4] [5] . The frequency of completion of a 6-month isoniazid regimen is slightly higher in some studies but may vary with the study population (Boston, 42.6%; San Diego, 74-86.7% for children aged <15 years) [6] [7] [8] .
Adverse effects to isoniazid are obstacles to completing isoniazid therapy [7, 9, 10] . Symptoms that occur during LTBI treatment have prevented individuals from completing isoniazid therapy [11, 12] . Cultural and ethnic factors may affect the acceptance or completion of isoniazid therapy [5] [6] [7] 13, 14] . However, it is unknown how these factors contribute to the adherence to isoniazid therapy by children. The purpose of the present study was (1) to determine the adherence to 9-month isoniazid therapy, with adherence measured objectively by monthly pill counts, and (2) to examine factors associated with the failure to complete therapy in patients aged 0-18 years. Part of the study methods in this paper was reported in a previous paper (Chang S, Nahid P, Eitzman, SR. Hepatotoxicity in children receiving isoniazid therapy for latent tuberculosis infection. Unpublished manuscript).
Materials and methods

Study setting
In this retrospective study, we reviewed an available sample of patients aged 0 to 18 years who were referred to either of 2 sites in a California county (a public health department and a pediatric LTBI clinic) and started isoniazid therapy between January 2005 and August 2011. The study was approved by the Committee on Human Research at University of California, San Francisco (IRB # 11-08230) and the institutional review board at Santa Clara Valley Medical Center (IRB # 11-059). Patients who had a diagnosis of LTBI were included if they (1) had a positive tuberculin skin test, (2) had a normal chest radiograph, and (3) were prescribed isoniazid for 9 months. Patients were excluded if they (1) were already receiving isoniazid therapy, (2) were previously treated and resumed isoniazid therapy because of interruption in treatment, (3) had active tuberculosis, (4) were treated with rifampin initially rather than isoniazid, or (5) had inadequate medical records such as missing monthly pill count.
Treatment of latent tuberculosis infection
Patients aged <2 years were referred to the public health department for follow-up through completion of treatment. The medical treatment of these children was performed by their primary care physician, with public health nurses who followed up with monthly home visits to assess medication adherence by pill count and to monitor for adverse effects.
Patients aged 2-18 years were evaluated and followed at the pediatric LTBI clinic by a nurse practitioner. These patients had a complete history, physical examination, and assessment of medication adherence by pill count and adverse effects before receiving each 1-month refill of medication. If a patient had ≥3-month break in LTBI therapy, the patient was required to restart treatment. Baseline serum transaminase tests (before starting therapy) were performed only in patients who were at increased risk for isoniazid-induced hepatitis, such as patients who received combination therapy (isoniazid with another potentially hepatotoxic drug) or patients who had a history of hepatitis or alcohol abuse. In patients who developed hepatitis during treatment, serum transaminase tests were repeated. After elevated serum transaminase levels subsided, rifampin therapy was offered to patients.
When pregnancy occurred, isoniazid was discontinued and restarted 2-3 months postpartum. There were no changes in this treatment protocol at the pediatric LTBI clinic from 2004 to 2012.
For children who were lost to follow-up or failed to keep clinic or home visits, efforts were made to contact patients by telephone or letter. There was no mechanism to track completion of treatment by patients when a family moved out of the county or transferred care to other medical providers in the community.
Definitions and measures
Completion of isoniazid therapy was defined as completion of 270 planned doses during a 9-month period or within 12 months according to American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America guidelines [1] . Medication adherence was measured by monthly pill count at home or clinic visits. Adverse effects were defined as symptoms occurring after the patient started therapy, determined from a checklist of symptoms associated with adverse effects to isoniazid used by the public health nurses and the LTBI clinic nurse practitioner. Symptoms of adverse effects that occurred between the start and end of therapy were recorded and divided by the number of actual home or clinic visits to obtain a rate of symptom experience over time.
Hepatitis was defined as elevation of serum transaminases > twice the upper limit of normal (ULN) during treatment. The researchers had a low threshold to diagnose hepatitis because the pediatric patients were difficult to follow and were less able to describe their own symptoms than adults; therefore, if the patients had transaminase levels >2 times the ULN, the patients were considered to have early hepatitis.
The parameters that were assessed as possible factors associated with failure to complete therapy included age, sex, race, reason for referral (TB risk classification), induration of tuberculin skin test, symptoms of adverse effect, serum transaminase levels, reason for not completing treatment, having a family member receiving treatment for tuberculosis, clinic location, and postal zip code. The outcome measure was status of completion.
Sample size and independency
Sample size was estimated by multiple logistic regression analysis (nQuery Advisor, version 4.0, Cork, Ireland). It was determined that a sample size of 1452 patients would be needed for a 2-group chi-square test with a 2-sided significance level of .05 and 80% power to detect a difference between groups having 85% and 90% frequency of completion (odds ratio, 1.59). When >1 child in a family was referred for evaluation and treatment, only the youngest child was entered as a case. The names of parents were used to identify children in the same family.
Data analysis
Tabulations and correlations between variables were performed with statistical software (SPSS, version 20.0, IBM Corp., Armonk, NY). We determined the percentage of missing data for each variable of interest, and variables were excluded from analysis when ≥20% data were missing. Significant predictors were identified with multiple logistic regression analysis based on P ≤ .05. There was no collinearity among predictors. Examination of the patterns of data showed that the number of cases for categorical predictors of the failure to complete therapy was too small, and the assumption of a linear relation between the symptom of adverse effect parameter and dependent variable was not met. To address these problems, we used the nonparametric bootstrap (SAS version 9.1, SAS, Cary, NC) and bias-corrected confidence intervals to identify significant effects. We reported the odds ratio and bias-corrected 95% confidence interval for each significant predictor [15] . Significant effects were determined on the basis of odds ratio not equal to 1. Exact logistic regression (SAS version 9.1, SAS, Cary, NC) was used to evaluate the relation between age and sex on the development of hepatitis.
Results
Frequency of completing isoniazid therapy
There were 1872 patients aged 0-18 years who were referred to the 2 clinical sites for a diagnosis of LTBI (Fig. 1 ). There were 174 patients (9%) who did not start isoniazid therapy including 47 patients (27%) who transferred care, 41 patients (24%) who moved, and 34 patients (20%) who were lost to follow-up. In the 1673 remaining patients (89%) who started therapy, 1587 patients satisfied the inclusion criteria (Fig. 1) . Most included patients completed 9 months of isoniazid therapy, and the frequency of therapy completion was greater in younger than older patients (P ≤ .001) ( Tables 1 and 2 ). In the 341 patients who did not Chil dren referred wit h diagnosis of LTBI (n = 1847)
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Most patients who started therapy were aged <15 years and Hispanic, and half of all patients who started therapy experienced ≥1 symptom of adverse effects (Table 1) . The most common symptoms of adverse effects were loss of appetite or abdominal pain; nausea, vomiting, or diarrhea; and headache (Table 1) .
Factors associated with failure to complete treatment
Sex, reason for referral (TB risk classification), induration of tuberculin skin test, having a family member receiving treatment for tuberculosis, clinic location, and postal zip code were not associated with failure to complete therapy (univariate analysis) and were excluded from further analysis. In multiple logistic regression, factors independently associated with failure to complete therapy included age 15-18 years, non-Hispanic race, development of hepatitis, and symptoms of adverse effects (Table 2) .
Factors associated with hepatitis
There were 49 children (3%) who had elevated serum transaminase level and received the diagnosis of hepatitis during treatment (Table 1) . Most patients who developed hepatitis were aged <15 years (Table 3) . Exact logistic regression showed that age and sex were not associated with the development of hepatitis, and the effect of age on the development of hepatitis did not differ by sex (Table 3) .
Discussion
The present results showed a high frequency of completing a 9-month course of isoniazid therapy (78%), greater in patients aged <15 years (Tables 1 and 2 ). The frequency of therapy completion in patients aged <15 years was greater than that reported in a previous study from Columbus, Ohio in which 54.4% patients aged <15 years completed therapy [5] . The present frequency of completing therapy for all patients aged <18 years (78%) was similar to that reported in a previous study from Houston, Texas (76%) [3] . In studies that define therapy completion as 6 months of isoniazid therapy, the frequency of therapy completion in patients aged <15 years is 74-86.7% [6, 7] . In the present study, 1138 of 1319 patients (86%) completed 6 months of isoniazid, similar to a previous study of a predominantly Hispanic population in San Diego (86.7%) [6] . In the Houston study, the directly observed therapy method used in half of the patients may have contributed to a higher frequency of completion [3] . In the San Diego study, many patients received behavioral intervention (47%) and source case investigation (36%) [6] . In the present study, only 3 children received directly observed therapy, and all others had self-administered therapy.
Several factors may have contributed to the high frequency of therapy completion in the present study. Pill counts by the nurse practitioner might increase parental diligence, increasing children's medication adherence. In addition, follow-up efforts included telephone calls and letters to remind patients of their appointments and retrieve patients lost to follow-up. Furthermore, medical care was accessible, with 5 LTBI clinic locations in the county for families in different geographic areas, and this may have increased the frequency of therapy completion over other settings in which tuberculosis care may be centralized.
In the present study, age 15-18 years, nonHispanic race, hepatitis, and symptoms of adverse effects were independently associated with failure to complete isoniazid therapy (Table 2) . These findings are consistent with those of other studies that showed that older age (15-18 years) is a factor in failure to complete therapy [7, 13, [16] [17] [18] . Younger children may be more likely than adolescents or adults to complete isoniazid therapy because of more intense parental supervision in younger patients.
The present finding that Hispanic patients were more likely to complete therapy than non-Hispanic patients (Table 2 ) also is consistent with previous reports [6, 7] . There may be greater openness to 
a N = 1587 subjects who started therapy; completion data available for 1576 subjects (99%). Data reported as number (%) or mean ± SD (range, minimum to maximum). b Significant effect by odds ratio and 95% confidence interval. c Data about race, available for 1563 patients. d Hepatitis defined as serum transaminase level >2 times the upper limit of normal. e Symptoms of adverse effects = total symptoms of adverse effects divided by total clinic or home visits during treatment.
LTBI therapy in parents from Central or South America than parents from Eastern Europe or Asia [5] . We confirmed that symptoms associated with adverse effects of isoniazid are an obstacle to completing therapy (Table 2) [7, 9, 10] . Symptoms such as abdominal pain or loss of appetite may occur with many minor illnesses, but patients may associate such symptoms with isoniazid and discontinue therapy. Hepatitis, defined by elevation of serum transaminase >2 times ULN, was a factor associated with failure to complete therapy (Table 2) , possibly because of the decision of the provider or patient. Patients who have hepatitis may require more frequent blood tests and may discontinue therapy because they may be reluctant to allow additional venipunctures [19] or may be concerned about drug safety. Further study is needed to evaluate the perceptions of children and parents about the adverse effects of drugs and blood tests required to treat hepatitis.
Although there was no significant interaction effect between age and sex on the development of hepatitis (Table 3) , a true effect might not have been evident because of insufficient statistical power. There is little information available about the effect of the interaction of age and sex on the development of hepatitis, and the effect of age on the development of hepatitis might differ between females and males aged <18 years. Future studies with larger sample sizes are necessary to evaluate the interaction between age and sex on the development of hepatitis.
The present study had several limitations. We used a convenience sample of patients with medical records from a single county. The sample was primarily from a specialty clinic in which many Hispanic children with public medical insurance were treated. Larger samples of ethnically diverse populations may be useful because ethnicity and socioeconomic status may be confounding variables for treatment adherence. In addition, the use of pill counts to quantify compliance may overestimate compliance in children who remove pills from bottles before the pill count. Another potential problem of using pill counts to determine compliance with drug therapy is that the outcome of therapy completion may have been biased by the response of parents to pill counts and the increased likelihood of adherence in the younger children supervised by a parent. Biomarker devices may generate accurate results and may be used to monitor adherence, such as urine strips [20, 21] or medication event monitoring systems that record the date and time when bottle caps are opened [22] , but these devices may be costly. Furthermore, data about the frequency of therapy completion were unavailable for 208 children who transferred care, moved, or were lost to follow-up (Fig. 1) ; these patients were included in the group that failed to complete therapy, and this may have caused an underestimation of the frequency of therapy completion for patients who may have completed therapy elsewhere. Similarly, for children who were lost to follow-up and who did not start therapy, we had no data about the reasons for not accepting isoniazid therapy.
The Pediatric Tuberculosis Collaborative Group recommended 3 types of intervention for promoting adherence to treatment of LTBI in children and adolescents: educational, organizational/support, and behavioral [2] . In the present study, our clinic provided organization support, with 5 convenient clinic sites, accessible open hours, and language capacity to communicate with Spanish-speaking patients. These provisions supported children and their parents in accessing and completing LTBI therapy in a county with a high frequency of tuberculosis [23] . However, additional investment in education and behavioral support for LTBI therapy is advised and may help address some of the risk factors identified for failure to complete therapy. The diagnosis and treatment of LTBI are important in the efforts to eliminate tuberculosis.
Conclusions
Failure to complete isoniazid therapy in patients aged 0-18 years was affected by older age, non-Hispanic race, development of hepatitis, and symptoms of adverse effects ( Table 2 ). The present findings suggest that additional support is needed for adolescents to complete LTBI therapy. Additional studies may focus on factors that affect the adherence of adolescents to LTBI therapy. More studies are needed to confirm that adolescent females may be at greater risk of developing hepatitis than adolescent males.
Funding
None.
Shiow-Huey Chang, RN, CNS, Ph.D. designed the study, collected and analyzed data, and wrote the manuscript. Sarah R. Eitzman, M.D. supplied research data, consulted about the data, and reviewed the manuscript. Payam Nahid, M.D., MPH performed methodological consultation and reviewed the manuscript. Maria Lourdes U. Finelli, MSN, FNP-C supplied research data and reviewed the manuscript. Each author listed on the manuscript has seen and approved the submission of this version of the manuscript.
